Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Servier Continues Oncology Winning Streak With Tibsovo Approval For MDS

Executive Summary

The targeted therapy won approval for myelodysplastic syndrome patients with IDH1 mutations, who have a higher propensity for progression to acute myeloid leukemia.

You may also be interested in...



ASCO 2023 - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO

Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.

Rigel Ready To Hit The Ground Running After Early AML Drug Approval

Rezlidhia, which was only recently licensed by Rigal from Novo Nordisk-owned Forma Therapeutics, should challenge the market dominance of Servier's Tibsovo in the IDH-1 inhibitor subset of acute myeloid leukemia patients. 

Tibsovo Approval Is A Stepping Stone For Servier’s Longer-Term Oncology Strategy

The privately held company expects five US FDA approvals by 2026 and will focus on big-ticket targets like immune checkpoints and cell therapies, CEO David K. Lee told Scrip.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel